Targeting therapy for homocysteic acid in the blood represents a potential recovery treatment for cognition in Alzheimer’s disease patients
| Autor: | Wataru Ukai, Tohru Hasegawa |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Aging
medicine.medical_specialty Amyloid Homocysteine Disease Antibodies Presenilin homocysteic acid in peripheral blood Mice chemistry.chemical_compound Alzheimer's cognitive decline Alzheimer Disease Internal medicine medicine Amyloid precursor protein Animals Methionine biology decreasing homocysteic acid in blood homocysteic acid in urine Cell Biology Homocysteic acid Disease Models Animal Endocrinology chemistry Research Perspective biology.protein Antibody Cognition Disorders Neuroscience |
| Zdroj: | Aging (Albany NY) |
| ISSN: | 1945-4589 |
| Popis: | At present, we have no reliable means of recovering cognitive impairment in Alzheimer's disease (AD) patients. We hypothesized that homocysteic acid (HA) in the blood might represent one such pathogen that could be excreted into the urine. Since DHA is known to reduce circulating levels of homocysteine, and since exercise attenuates this effect, it follows that supplementation of the diet with DHA, along with increased levels of physical activity, may help to reduce cognitive impairment in AD patients. Our hypothesis was proven to be correct because memory problems in 3xTg- AD mice (a model for AD in which animals develop amyloid pathology), and in a mouse model of familial AD, were recovered following treatment with an anti-HA antibody and not by amyloid treatment. Interestingly, 3xTg-AD mice with amyloid pathology showed increased levels of HA level. This could perhaps be explained by the fact that amyloid precursor protein and/or presenilin increases calcium influx, which could then increase levels of superoxide and consequently increase levels of HA from homocysteine or methionine. Our hypothesis is also partially supported by an open clinical trial of certain dietary supplements that has shown impressive results. Also there are other treatments hypothesis which would be possible for the effective therapies, such as ribonucleoprotein therapy, a β-secretase inhibitor treatment and the metabolic enhancement treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|